Annual report pursuant to Section 13 and 15(d)

Accrued Liabilities and Other Payables (Tables)

v3.20.1
Accrued Liabilities and Other Payables (Tables)
12 Months Ended
Dec. 31, 2019
Payables and Accruals [Abstract]  
Schedule of accrued liabilities and other payables
    December 31,
2019
    December 31,
2018
 
Accrued payroll liability   $ 373,083     $ 529,472  
Accrued professional fees     1,243,190       166,077  
Accrued research and development fees *     650,000       -  
Insurance payable     -       45,088  
Accrued directors' compensation     115,000       17,500  
Accounts payable     84,316       6,695  
Interest payable     -       75,342  
Other     104,595       120,017  
    $ 2,570,184     $ 960,191  

 

* In accordance with the strategic partnership agreement with Weill Cornell's cGMP Cellular Therapy Facility and Laboratory signed on August 6, 2018, the Company provides $400,000 annually to Weill Cornell's cGMP Cellular Therapy Facility and Laboratory to support the co-development projects. In addition, the Company will on an annual basis send one scientist or clinician to Weill Cornell's cGMP Cellular Therapy Facility and Laboratory to receive relevant training for three to six months. As of December 31, 2019, the accrued and unpaid research and development fees related to this agreement was $150,000.